Drug Profile
Research programme: cancer vaccines - Ayala Pharmaceuticals
Alternative Names: Lm-LLO-CA9; Lm-LLO-cHER2-VEGFR2; ADXS-TNBC; Live attenuated Listeria-based vaccines for cancer - Ayala Pharmaceuticals/NCI; Lm-LLO-VEGF2; Lovaxin M; Lovaxin S; Lovaxin SCCE; Lovaxin WLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Ayala Pharmaceuticals; City of Hope National Medical Center
- Class Cancer vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Neoplasm protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Leukaemia; Lymphoma